JP7747645B2 - グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法 - Google Patents

グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法

Info

Publication number
JP7747645B2
JP7747645B2 JP2022550781A JP2022550781A JP7747645B2 JP 7747645 B2 JP7747645 B2 JP 7747645B2 JP 2022550781 A JP2022550781 A JP 2022550781A JP 2022550781 A JP2022550781 A JP 2022550781A JP 7747645 B2 JP7747645 B2 JP 7747645B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022550781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516286A5 (enExample
JP2023516286A (ja
Inventor
ファン シャオフー
マオ ジェ
ゾアン キウチュアン
ワン ルイシュエ
Original Assignee
レジェンド バイオテック アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レジェンド バイオテック アイルランド リミテッド filed Critical レジェンド バイオテック アイルランド リミテッド
Publication of JP2023516286A publication Critical patent/JP2023516286A/ja
Publication of JP2023516286A5 publication Critical patent/JP2023516286A5/ja
Application granted granted Critical
Publication of JP7747645B2 publication Critical patent/JP7747645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
JP2022550781A 2020-02-27 2021-02-26 グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法 Active JP7747645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/076937 2020-02-27
CN2020076937 2020-02-27
PCT/CN2021/078203 WO2021170100A1 (en) 2020-02-27 2021-02-26 Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023516286A JP2023516286A (ja) 2023-04-19
JP2023516286A5 JP2023516286A5 (enExample) 2024-02-29
JP7747645B2 true JP7747645B2 (ja) 2025-10-01

Family

ID=77490732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550781A Active JP7747645B2 (ja) 2020-02-27 2021-02-26 グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法

Country Status (12)

Country Link
US (1) US20230088461A1 (enExample)
EP (1) EP4110912A4 (enExample)
JP (1) JP7747645B2 (enExample)
KR (1) KR20220146456A (enExample)
CN (1) CN115151639A (enExample)
AU (1) AU2021225978A1 (enExample)
BR (1) BR112022016958A2 (enExample)
CA (1) CA3170023A1 (enExample)
IL (1) IL295774A (enExample)
MX (1) MX2022010360A (enExample)
WO (1) WO2021170100A1 (enExample)
ZA (1) ZA202209069B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260116991A1 (en) * 2021-02-03 2026-04-30 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Monoclonal antibody for specifically recognizing glypican-3, and application thereof
JP2024507958A (ja) * 2021-02-26 2024-02-21 ナンジン レジェンド バイオテック カンパニー，リミテッド 外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
JP2025524921A (ja) * 2022-07-29 2025-08-01 レジェンド バイオテック アイルランド リミテッド 細胞療法の持続性を促進するための方法
EP4562046A1 (en) * 2022-07-29 2025-06-04 Legend Biotech Ireland Limited Claudin-6 binding moieties and uses thereof
CN117025541B (zh) * 2023-08-15 2025-10-17 福建医科大学附属协和医院 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途
KR20250116580A (ko) * 2024-01-24 2025-08-01 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체를 이용한 키메라 항원 수용체 t 세포

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232848A (ja) 2004-07-09 2009-10-15 Chugai Pharmaceut Co Ltd 抗グリピカン３抗体
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2019161174A1 (en) 2018-02-15 2019-08-22 Seattle Genetics, Inc. Glypican 3 antibodies and conjugates thereof
WO2020017479A1 (ja) 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050020806A (ko) * 2002-05-23 2005-03-04 써니브룩 앤드 우먼스 칼리지 헬스 사이언시즈 센터 간세포암의 진단
CN1894587A (zh) * 2003-10-29 2007-01-10 财团法人熊本高新技术产业财团 恶性黑色素瘤(melanoma)的诊断试剂
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
CN104520331B (zh) * 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
ES2851123T1 (es) * 2014-09-26 2021-09-03 Baylor College Medicine Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
US20160208018A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2018059549A1 (en) * 2016-09-30 2018-04-05 Novartis Ag Immune effector cell therapies with enhanced efficacy
TWI831365B (zh) * 2017-01-10 2024-02-01 國立大學法人山口大學 抗ｇｐｃ３抗體
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN110684120B (zh) * 2019-10-12 2023-03-07 华夏源（上海）细胞基因工程股份有限公司 一种靶向gpc3的嵌合抗原受体及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232848A (ja) 2004-07-09 2009-10-15 Chugai Pharmaceut Co Ltd 抗グリピカン３抗体
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2019161174A1 (en) 2018-02-15 2019-08-22 Seattle Genetics, Inc. Glypican 3 antibodies and conjugates thereof
WO2020017479A1 (ja) 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ

Also Published As

Publication number Publication date
CN115151639A (zh) 2022-10-04
EP4110912A4 (en) 2024-07-10
ZA202209069B (en) 2023-10-25
AU2021225978A1 (en) 2022-09-08
KR20220146456A (ko) 2022-11-01
CA3170023A1 (en) 2021-09-02
US20230088461A1 (en) 2023-03-23
WO2021170100A1 (en) 2021-09-02
EP4110912A1 (en) 2023-01-04
MX2022010360A (es) 2022-09-21
BR112022016958A2 (pt) 2022-10-25
JP2023516286A (ja) 2023-04-19
IL295774A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
WO2021121228A1 (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
US20260027209A1 (en) Claudin-6 binding moieties and uses thereof
US20230192883A1 (en) Cd19 binding molecules and uses thereof
WO2021170100A1 (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
IL294683A (en) Chimeric Antigen Receptors Based on Single-Site Antibodies and Methods for Using Them
WO2022127871A1 (en) Gucy2c binding molecules and uses thereof
WO2024041650A1 (en) Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2022012682A1 (en) Cd22 binding molecules and uses thereof
WO2022012680A1 (en) Cd20 binding molecules and uses thereof
WO2024067762A1 (en) Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
WO2026103881A1 (en) Bcma binding moieties and uses thereof
HK40079774A (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240219

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250918

R150 Certificate of patent or registration of utility model

Ref document number: 7747645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150